DoMore Diagnostics secures EIC Accelerator grant - awarded up to €10 million financing
DoMore Diagnostics secures EIC Accelerator grant - awarded up to €10 million financing
DoMore Diagnostics and Paige enters commercial partnership and make Histotype Px® Colorectal available on Paige’s AppLab™ Marketplace
Histotype Px® Colorectal will be added to Paige’s new AppLab™ Marketplace.
NOK 16 million public grant awarded by the Research Council of Norway to DoMore Diagnostics
DoMore Diagnostics has been awarded NOK 16 million in public grant funding from The Research Council of Norway for the project “Clinical validation and implementation of the AI-based digital biomarker Histotype Px® to personalize treatment in colorectal cancer”.
DoMore Diagnostics and Stavanger University Hospital to Collaborate on the Digital Biomarker Histotype Px® Colorectal to Personalize Cancer Treatment
Under the agreement, Stavanger University Hospital will validate Histotype Px® Colorectal biomarker in patients from the Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer (ACROBATICC) study and test the clinical utility of the digital biomarker in a group of Norwegian stage II/III colorectal cancer patients.
DoMore Diagnostics welcomes Goran Kovačević as our new Senior Software Developer
DoMore Diagnostics is pleased to announce the appointment of Goran Kovačević as Senior Software Developer. His expertise in architecting secure cloud systems will be an important contribution to the continued growth of the company and wide distribution of Histotype Px.
DoMore Diagnostics And Proscia Partner To Inform Personalized Treatment Decisions For Colorectal Cancer Patients
OSLO and PHILADELPHIA – August 30, 2023 – DoMore Diagnostics, a leader in deep learning precision diagnostics for digital pathology, and Proscia®, a leading provider of digital and computational pathology solutions, have partnered to help pathologists predict outcomes for colorectal cancer (CRC) patients. The collaboration paves the way for integrating artificial intelligence (AI)-powered clinical decision support into routine pathology workflows, unlocking new insights that can guide increasingly precise treatment decisions and ensure patients receive optimal care.
DoMore Diagnostics and The Ohio State University Wexner Medical Center to Collaborate on Digital Biomarker Histotype Px® Colorectal to Personalize Cancer Treatment
Under this agreement, The Ohio State University Wexner Medical Center will implement and validate DoMore Diagnostics' Histotype Px® Colorectal digital biomarker in a group of U.S. patients to determine whether the test can help guide real-life decisions for patients with stage II and stage III colorectal cancer.
DoMore Diagnostics welcomes Andreas Berg Storsve as our new VP Operations
DoMore Diagnostics is pleased to announce the appointment of Andreas Berg Storsve, PhD as VP Operations. Dr. Storsve will join the management team and take a leading role in driving partnerships and business development activities forward.
DoMore Diagnostics has successfully completed ISO 13485 certification
DoMore Diagnostics today announced that the quality management system (QMS) has been certified as compliant with the ISO 13485 standard. The certification audit process was conducted by DNV (notified body).
DoMore Diagnostics announces expansion of the Scientific Advisory Board
DoMore Diagnostics announces Dr. Takayuki Yoshino, MD, Professor Hans-Joachim Schmoll, MD, Dr. Jakob Nikolas Kather, MD, and Dr. Marc Peeters, MD are joining the Scientific Advisory Board. The four leaders in GI oncology will undoubtedly make vital contributions in bringing the company forward.
DoMore Diagnostics announces successful integration with the Sectra software platform for digital pathology
DoMore Diagnostics today announced that its Histotype Px Colorectal outcome prediction marker is available on the Sectra pathology imaging platform, facilitating seamless and easy access to this cutting-edge technology.
Impressive results with The Histotype Px Colorectal cancer marker published in The Lancet Oncology
DoMore Diagnostics today announced that The Lancet Oncology has published an article documenting that the Histotype Px Colorectal algorithm even more accurately predicts patient outcomes when used in combination with tumor and lymph node status.
DoMore Diagnostics achieves CE-IVD mark for Histotype Px® Colorectal, an AI algorithm that predict patient outcomes in colorectal cancer patients by analyzing standard histology images
DoMore Diagnostics achieves CE-IVD mark for Histotype Px® Colorectal, an AI algorithm that predict patient outcomes in colorectal cancer patients by analyzing standard histology images
DoMore Diagnostics congratulates Prof. Håvard Danielsen with the King Olav V´s Cancer Research Prize for 2022
DoMore Diagnostics congratulates Prof. Håvard Danielsen with the King Olav V´s Cancer Research Prize for 2022. The prestigious prize was handed over by HM Kong Harald V on behalf of the Norwegian Cancer Society in Oslo on May 9.
DoMore Diagnostics announces that Sophie Grindstad and Ole J. Dahlberg join as new members to the Board of Directors
DoMore Diagnostics announces that Sophie Grindstad and Ole J. Dahlberg have been elected as new members to the Board of Directors
DoMore Diagnostics announces the formation of our Scientific Advisory Board
World renowned experts joining the Scientific Advisory Board to support the development of DoMore Diagnostics